{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:27:52Z","timestamp":1718756872835},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cyto.2024.156630","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:12:40Z","timestamp":1714536760000},"page":"156630","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic variations in immune mediators and prostate cancer risk: A field synopsis with Bayesian calculations"],"prefix":"10.1016","volume":"179","author":[{"given":"Matheus","family":"Santos Freire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Victor de Oliveira Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayane","family":"Moura Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcia","family":"Socorro Silva Lima Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carlos Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Luiz Ara\u00fajo Bentes Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Rodolfo Pereira da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Fernando Marques Barcellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.cyto.2024.156630_b0005","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.cyto.2024.156630_b0015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156630_b0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1385\/MO:19:3:133","article-title":"Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma","volume":"19","author":"Jurisi\u0107","year":"2002","journal-title":"Med. Oncol."},{"key":"10.1016\/j.cyto.2024.156630_b0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","article-title":"The role of cytokines in the regulation of NK cells in the tumor environment","volume":"117","author":"Konjevi\u0107","year":"2019","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.cyto.2024.156630_b0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14789450.2020.1845654","article-title":"Multiomic analysis of cytokines in immuno-oncology","volume":"17","author":"Jurisic","year":"2020","journal-title":"Expert Rev. Proteomics"},{"issue":"6","key":"10.1016\/j.cyto.2024.156630_b0035","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00432-019-02917-z","article-title":"IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1\/2","volume":"145","author":"Chen","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1158\/1541-7786.MCR-19-0595","article-title":"IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer","volume":"18","author":"Maynard","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"14","key":"10.1016\/j.cyto.2024.156630_b0045","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.3390\/ijms21145036","article-title":"Hereditary predisposition to prostate cancer: from genetics to clinical implications","volume":"21","author":"Brand\u00e3o","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0050","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.clbc.2020.07.014","article-title":"Male breast cancer risk assessment and screening recommendations in high-risk men who undergo genetic counseling and multigene panel testing","volume":"21","author":"Gaddam","year":"2021","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.cyto.2024.156630_b0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"11","key":"10.1016\/j.cyto.2024.156630_b0060","first-page":"6057","article-title":"Investigation of Interleukin-1\u03b2 Polymorphisms in Prostate Cancer","volume":"35","author":"Yencilek","year":"2015","journal-title":"Anticancer Res"},{"issue":"670","key":"10.1016\/j.cyto.2024.156630_b0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.gene.2018.05.104","article-title":"Associations of interleukin-6 gene polymorphisms with cancer risk: Evidence based on 49,408 cancer cases and 61,790 controls","volume":"5","author":"Zhou","year":"2018","journal-title":"Gene"},{"issue":"2021","key":"10.1016\/j.cyto.2024.156630_b0070","first-page":"3825525","article-title":"Relevance of interleukins 6 and 8 single nucleotide polymorphisms in prostate cancer: a multicenter study","volume":"6","author":"Ghazy","year":"2021","journal-title":"Prostate Cancer."},{"issue":"28","key":"10.1016\/j.cyto.2024.156630_b0075","doi-asserted-by":"crossref","first-page":"45994","DOI":"10.18632\/oncotarget.17522","article-title":"The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies","volume":"8","author":"Men","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cyto.2024.156630_b0080","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jfma.2019.10.016","article-title":"Association between interleukin-8 rs4073 polymorphism and prostate cancer: a meta-analysis","volume":"119","author":"Chen","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.cyto.2024.156630_b0085","article-title":"Interleukin-10 (IL-10) gene polymorphisms and prostate cancer susceptibility: evidence from a meta-analysis","volume":"25","author":"Yadav","year":"2021","journal-title":"Gene Rep."},{"key":"10.1016\/j.cyto.2024.156630_b0090","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/506150a","article-title":"Statistical errors: P values, the'gold standard'of statistical validity, are not as reliable as many scientists assume","volume":"506","author":"Nuzzo","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cyto.2024.156630_b0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jnci\/djh075","article-title":"Assessing the probability that a positive report is false: an approach for molecular epidemiology studies","volume":"96","author":"Wacholder","year":"2004","journal-title":"J. Natl Cancer Inst."},{"issue":"2","key":"10.1016\/j.cyto.2024.156630_b0100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1086\/519024","article-title":"A Bayesian measure of the probability of false discovery in genetic epidemiology studies","volume":"81","author":"Wakefield","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cyto.2024.156630_b0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ije\/dym159","article-title":"Assessment of cumulative evidence on genetic associations: interim guidelines","volume":"37","author":"Ioannidis","year":"2008","journal-title":"Int. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s13277-013-1092-5","article-title":"TGF\u03b21 Leu10Pro polymorphism contributes to the development of prostate cancer: evidence from a meta-analysis","volume":"35","author":"Cai","year":"2014","journal-title":"Tumour Biol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156630_b0120","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s13277-013-1250-9","article-title":"Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer","volume":"35","author":"Chen","year":"2014","journal-title":"Tumour Biol."},{"issue":"39","key":"10.1016\/j.cyto.2024.156630_b0125","doi-asserted-by":"crossref","first-page":"66204","DOI":"10.18632\/oncotarget.19857","article-title":"Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.cyto.2024.156630_b0130","doi-asserted-by":"crossref","first-page":"13391","DOI":"10.4238\/2015.October.28.1","article-title":"Lack of association between the cyclooxygenase 2\u2013765G>C polymorphism and prostate cancer risk: a meta-analysis","volume":"14","author":"Feng","year":"2015","journal-title":"Genet. Mol. Res."},{"issue":"11","key":"10.1016\/j.cyto.2024.156630_b0135","doi-asserted-by":"crossref","first-page":"e6126","DOI":"10.1097\/MD.0000000000006126","article-title":"Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0140","first-page":"1227","article-title":"Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis","volume":"8","author":"Luo","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"9","key":"10.1016\/j.cyto.2024.156630_b0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1746-1596-9-74","article-title":"Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis","volume":"25","author":"Ma","year":"2014","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.cyto.2024.156630_b0150","first-page":"1967","article-title":"Meta-analysis on the possible role of interluekin-10 rs1800896 polymorphism in association with prostate cancer susceptibility","volume":"10","author":"Ruan","year":"2017","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"20","key":"10.1016\/j.cyto.2024.156630_b0155","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.7314\/APJCP.2014.15.20.8741","article-title":"Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk","volume":"15","author":"Xu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.cyto.2024.156630_b0160","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s13277-013-1173-5","article-title":"Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis","volume":"35","author":"Xu","year":"2014","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.cyto.2024.156630_b0165","first-page":"182","article-title":"Association between the 8473T>C polymorphism of PTGS2 and prostate cancer risk: a metaanalysis including 24,716 subjects","volume":"36","author":"Yang","year":"2013","journal-title":"Onkologie"},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41065-020-00125-1","article-title":"No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-\u03b1 gene and susceptibility to prostate cancer: a comprehensive meta-analysis","volume":"157","author":"Yin","year":"2020","journal-title":"Hereditas"},{"issue":"6","key":"10.1016\/j.cyto.2024.156630_b0175","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.31557\/APJCP.2019.20.6.1595","article-title":"Association between IL-18 -607 C\/A polymorphism and the risk of prostate cancer: a meta-analysis of case-control studies","volume":"20","author":"Yuanyuan","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"13","key":"10.1016\/j.cyto.2024.156630_b0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2172-13-14","article-title":"Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2012","journal-title":"BMC Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156630_b0185","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.4238\/2012.June.15.13","article-title":"Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer","volume":"11","author":"Zhang","year":"2012","journal-title":"Genet. Mol. Res."},{"issue":"3","key":"10.1016\/j.cyto.2024.156630_b0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/modpathol.2008.236","article-title":"TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas","volume":"22","author":"Lotan","year":"2009","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.cyto.2024.156630_b0195","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/modpathol.2012.236","article-title":"Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions","volume":"26","author":"Kluth","year":"2013","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156630_b0200","doi-asserted-by":"crossref","first-page":"T95","DOI":"10.1530\/ERC-21-0149","article-title":"The tumor microenvironment and immune responses in prostate cancer patients","volume":"28","author":"Kwon","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"11","key":"10.1016\/j.cyto.2024.156630_b0205","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.cyto.2024.156630_b0210","article-title":"Prognostic Value of Genes and Immune Infiltration in Prostate Tumor Microenvironment","volume":"30","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.cyto.2024.156630_b0215","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/MCB.00090-14","article-title":"Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression","volume":"34","author":"Garcia","year":"2014","journal-title":"Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.cyto.2024.156630_b0220","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/CJI.0000000000000045","article-title":"Analysis of the expression of interleukins, interferon \u03b2, and nuclear factor-\u03ba B in prostate cancer and their relationship with biochemical recurrence","volume":"37","author":"Eir\u00f3","year":"2014","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.cyto.2024.156630_b0225","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11033-022-08077-7","article-title":"Association between interleuleukin-1\u03b2 polymorphism (rs16944) and biomarkers levels in Iraqi patients with prostate cancer","volume":"50","author":"Abed","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"8","key":"10.1016\/j.cyto.2024.156630_b0230","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/0008-5472.CAN-05-3987","article-title":"Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer","volume":"66","author":"Michaud","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.cyto.2024.156630_b0235","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/carcin\/bgm277","article-title":"Interactions of cytokine gene polymorphisms in prostate cancer risk","volume":"29","author":"Zabaleta","year":"2008","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.cyto.2024.156630_b0240","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3343\/alm.2015.35.3.283","article-title":"Meta-analysis of genetic association studies","volume":"35","author":"Lee","year":"2015","journal-title":"Ann. Lab. Med."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2024.156630_b0245","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0165-5728(00)00407-0","article-title":"Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation","volume":"112","author":"Giedraitis","year":"2001","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.cyto.2024.156630_b0250","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1089\/jir.2006.26.706","article-title":"The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death","volume":"26","author":"Hodge","year":"2006","journal-title":"J. Interferon Cytokine Res."},{"issue":"66","key":"10.1016\/j.cyto.2024.156630_b0255","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5604\/17322693.1000980","article-title":"The impact of IL18 gene polymorphisms on mRNA levels and interleukin-18 release by peripheral blood mononuclear cells","volume":"20","author":"Dziedziejko","year":"2012","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"issue":"15","key":"10.1016\/j.cyto.2024.156630_b0260","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/pros.23055","article-title":"Functional genetic variability at promoters of pro-(IL-18) and anti-(IL-10) inflammatory affects their mRNA expression and survival in prostate carcinoma patients: Five year follow-up study","volume":"75","author":"Dwivedi","year":"2015","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.cyto.2024.156630_b0265","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tig.2004.06.014","article-title":"Meta-analysis of genetic association studies","volume":"20","author":"Munaf\u00f2","year":"2004","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jcp.2005.036442","article-title":"Diagnosis of adenocarcinoma in prostate needle biopsy tissue","volume":"60","author":"Humphrey","year":"2007","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156630_b0275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/PAS.0000000000001202","article-title":"Transatlantic Prostate Group. Histopathologic false-positive diagnoses of prostate cancer in the age of immunohistochemistry","volume":"43","author":"Beltran","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.cyto.2024.156630_b0280","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2490-9-14","article-title":"A systematic review of the diagnostic accuracy of prostate specific antigen","volume":"10","author":"Harvey","year":"2009","journal-title":"BMC Urol."},{"issue":"155361","key":"10.1016\/j.cyto.2024.156630_b0285","article-title":"Polymorphisms in the interleukin genes and chronic periodontitis: A field synopsis and revaluation by Bayesian approaches","volume":"138","author":"da Silva","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2024.156630_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155955","article-title":"Polymorphisms in immune-mediator genes and the risk of dengue virus infection: Lights from a systematic revaluation by Bayesian approaches","volume":"157","author":"Leal","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2024.156630_b0295","doi-asserted-by":"crossref","unstructured":"A. Penha Mesquita, A. Victor Oliveira Monteiro, A. Luiz Ara\u00fajo Bentes Leal, L. Dos Santos Pessoa, J. de Siqueira Amorim J\u00fanior, J. Rog\u00e9rio Souza Monteiro, A. Andrade de Sousa, D. Fernando Pereira Vasconcelos, A. Carolina Alves de Oliveira, A. Le\u00e3o Pereira, F. Rodolfo Pereira da Silva, Gene variations related to the hepatocellular carcinoma: results from a field synopsis and Bayesian revaluation. Gene 869 (2023) 147392. doi: 10.1016\/j.gene.2023.147392.","DOI":"10.1016\/j.gene.2023.147392"},{"issue":"7","key":"10.1016\/j.cyto.2024.156630_b0300","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/ijms22073753","article-title":"Hereditary prostate cancer: genes related, target therapy and prevention","volume":"22","author":"Vietri","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2024.156630_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-007-0445-9","article-title":"Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls","volume":"123","author":"Kavvoura","year":"2008","journal-title":"Hum. Genet."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T22:01:10Z","timestamp":1718748070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":61,"alternative-id":["S1043466624001339"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156630","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic variations in immune mediators and prostate cancer risk: A field synopsis with Bayesian calculations","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156630"}}